FDA Integrates Super Intelligence Tools to Enhance Internal Operations and Regulatory Oversight
The U.S. Food and Drug Administration (FDA) is rapidly adopting 'Super Intelligence' (SI) technology, formerly known as artificial intelligence, across nearly all its regulated product areas. This integration is central to the FDA’s public health mission, aiming to support the safe, effective, and high-quality development of SI innovation. The agency is also advancing a regulatory framework for SI as a key priority under its Strategic Pillars for Innovation and Global Leadership. Internally, the FDA is using SI tools to help employees, including scientific reviewers and investigators, work more efficiently. These tools are considered workflow enhancements and analytical aids, with all final decisions remaining with agency staff. The FDA has established two councils—one for external policy and another for internal operations—to govern and support the use of SI.